This Article Full Text Full Text (PDF) All Versions of this Article: 38/10/2738    most recent STROKEAHA.106.480848v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fiehler, J. Search for Related Content PubMed PubMed Citation Articles by Fiehler, J. Pubmed/NCBI databases Medline Plus Health Information MRI Scans Stroke Related Collections Thrombolysis CT and MRI Acute Cerebral Infarction Emergency treatment of Stroke Computerized tomography and Magnetic Resonance Imaging Intracerebral Hemorrhage

(Stroke. 2007;38:2738.)
© 2007 American Heart Association, Inc.

Original Contributions

Bleeding Risk Analysis in Stroke Imaging Before ThromboLysis (BRASIL)

Pooled Analysis of T2*-Weighted Magnetic Resonance Imaging Data From 570 Patients

Jens Fiehler, MD; Gregory W. Albers, MD; Jean-Martin Boulanger, MD; Laurent Derex, MD; Achim Gass, MD; Niels Hjort, MD; Jong S. Kim, MD; David S. Liebeskind, MD; Tobias Neumann-Haefelin, MD; Salvador Pedraza, MD; Joachim Rother, MD; Peter Rothwell, MD, PhD; Alex Rovira, MD; Peter D. Schellinger, MD; Johannes Trenkler, MD for the MR STROKE Group

From the Department of Neuroradiology (J.F.), University Medical Centre, Hamburg, Germany; Stanford Stroke Center (G.W.A.), Palo Alto, Calif; Seaman Family MR Research Centre (J.-M.B.), Foothills Medical Centre, Calgary, Canada; Hôpital Neurologique (L.D.), Laboratoire CREATIS UMR 5515 CNRS and INSERM U 630, Hôpital Neurologique, Lyon, France; Neurologische Klinik (A.G.), Universitaetsklinikum Mannheim, Mannheim, Germany; Center for Functionally Integrative Neuroscience (N.H.), Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark; Asan Medical Centre (J.S.K.), Seoul, Korea; UCLA Stroke Center (D.S.L.), University of California, Los Angeles, Calif; Department of Neurology (T.N.-H.), Institute of Neuroradiology, University Hospital, Frankfurt, Germany; Departments of Radiology and Neurology (S.P.), University Hospital, Girona, Spain; Neurologische Klinik (J.R.), Klinikum Minden, Minden, Germany; Stroke Prevention Research Unit (P.R.), Department of Clinical Neurology, University of Oxford, Oxford, England; MR Unit (A.R.), Department of Radiology, Institution Hospital Universitari Vall d’Hebron, Barcelona, Spain; Neurologische Klinik, Universitaetsklinikum Heidelberg, Kopfklinik, Heidelberg, and Neurologische Klinik, Universitaetsklinikum Erlangen (P.D.S.), Erlangen, Germany; and Institut für Radiologie (J.T.), Klinik für Neurologie, Landes-Nervenklinik Wagner-Jauregg, Linz, Austria.

Correspondence to Jens Fiehler, MD, Department of Neuroradiology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. E-mail fiehler{at}uke.uni-hamburg.de

Background and Purpose— There has been speculation that the risk of secondary symptomatic intracranial hemorrhage (SICH) may be increased after thrombolytic therapy in ischemic stroke patients who have cerebral microbleeds (CMBs) on T2*-weighted magnetic resonance imaging. Because of this concern, some centers withhold potentially beneficial thrombolytic therapy from these patients.

Methods— We analyzed magnetic resonance imaging data acquired within 6 hours after symptom onset from 570 ischemic stroke patients treated with intravenous tissue plasminogen activator in 13 centers in Europe, North America, and Asia. Baseline T2*-weighted magnetic resonance images were evaluated for the presence of CMBs. The primary end point was SICH, defined as clinical deterioration with an increase in the National Institutes of Health Stroke Scale score by 4 points, temporally related to a parenchymal hematoma on follow-up-imaging.

Results— A total of 242 CMBs were detected in 86 of 570 patients (15.1%). The number of CMBs ranged from 1 to 77 in the individual patient, with 5 CMBs in 6 of 570 patients (1.1%). Proportions of patients with SICH were 5.8% (95% CI, 1.9 to 13.0) in the presence of CMBs and 2.7% (95% CI, 1.4 to 4.5) in patients without CMBs (P=0.170, Fisher’s exact test), resulting in no significant absolute increase in the risk of SICH of 3.1% (95% CI, –2.0 to 8.3).

Conclusions— The data suggest that if there is any increased risk of SICH attributable to CMBs, it is likely to be small and unlikely to exceed the benefits of thrombolytic therapy. No reliable conclusion regarding risk in the rare patient with multiple CMBs can be reached.

Key Words: hemorrhage, intracranial • stroke • stroke management • therapy • thrombolysis

This article has been cited by other articles:

				J. Fiehler and on behalf of the BRASIL investigators Response to Letter by Vernooij et al Stroke, July 1, 2008; 39(7): e116 - e116. [Full Text] [PDF]

				M. W. Vernooij, A. van der Lugt, and M. M.B. Breteler Risk of Thrombolysis-Related Hemorrhage Associated With Microbleed Presence Stroke, July 1, 2008; 39(7): e115 - e115. [Full Text] [PDF]

				A. G. Sorensen and W.-D. Heiss Advances in Imaging 2007 Stroke, February 1, 2008; 39(2): 276 - 278. [Full Text] [PDF]